 |  |
 |  |  | |||||||
|
--- Celebrex Trial Halted After Heart Attacks
Reiter's Information & Support Group Inc. RISG.ORG http://www.risg.org Spondyloarthropathies: Reactive Arthritis (Reiter's Syndrome), Ankylosing Spondylitis, Psoriatic Arthritis, IBD, and all they may bring. Uveitis, Iritis, Conjunctivitis etc. Current News Updates. http://www.risg.org/newspro/currnews.shtml You can subscribe/unsubscribe from the same page. The information contained in these articles may or may not reflect the beliefs of RISG.ORG its staff or members. We are a nonprofit organization created and maintained by volunteers but sustained by your tax-deductible contributions. Your contribution to RISG.ORG is tax deductible. Credit Card, Snail Mail or PayPal http://www.risg.org/contributions.htm rick@risg.org This information is for informational purposes only and is not a substitute for professional medical advice. --------------------------------- RISG.ORG Current news supplement. Week 12-16-04 --------------------------------- Posted Friday, December 17, 2004 by Rick: Celebrex Trial Stopped After Heart Attacks Reuters, NY - 28 minutes ago NEW YORK (Reuters) - A government-sponsored trial of Pfizer Inc.'s blockbuster arthritis drug Celebrex was halted after patients taking the medicine had more ... (link:http://www.reuters.com/newsArticle.jhtml?type=healthNews&storyID=7126619) http://www.reuters.com/newsArticle.jhtml?type=healthNews&storyID=7126619 Pfizer Statement On New Information Regarding Cardiovascular ... mysan.de, Germany - 2 hours ago ... FirstCall/ -- Pfizer Inc said it received new information last night about the cardiovascular safety of its COX-2 inhibitor Celebrex (celecoxib) based on an ... (link:http://www.mysan.de/international/article16230.html) http://www.mysan.de/international/article16230.html Pfizer Reports Heart Risk With Celebrex NewsFactor Network, CA - 12 minutes ago After finding that patients taking 400mg to 800mg of Celebrex daily were found to have a 2.5 times greater risk of experiencing heart problems than those who ... (link:http://business.newsfactor.com/story.xhtml?story_title=Pfizer-Reports-Heart-Risk-With-Celebrex&story_id=112.3261776&category=business) http://business.newsfactor.com/story.xhtml?story_title=Pfizer-Reports-Heart-Risk-With-Celebrex&story_id=112.3261776&category=business Pfizer halts Celebrex sales in Turkey Seattle Post Intelligencer, WA - Nov 24, 2004 said Wednesday it has temporarily halted sales of its pain reliever Celebrex in Turkey because health authorities there sought to include very restrictive ... (link:http://seattlepi.nwsource.com/business/apbiz_story.asp?category=1310&slug=Pfizer Celebrex) http://seattlepi.nwsource.com/business/apbiz_story.asp?category=1310&slug=Pfizer Celebrex Study: Celebrex Safer Than Vioxx CBS News - Dec 7, 2004 (AP) New research suggests that top-selling pain reliever Celebrex does not carry the same heart attack risk as Vioxx, a ... "Vioxx and Celebrex look different. ... (link:http://www.cbsnews.com/stories/2004/12/07/health/main659540.shtml) http://www.cbsnews.com/stories/2004/12/07/health/main659540.shtml Pfizer: Celebrex Increases Risk of Heart Problems NEW YORK - Pfizer Inc. (PFE) said Friday it found an increased risk of heart problems with patients taking its painkiller Celebrex, a drug that is in the same class as Merck's Vioxx, which was pulled from the market in September because of safety concerns. (link:http://www.foxnews.com/story/0,2933,141838,00.html) http://www.foxnews.com/story/0,2933,141838,00.html Rick Hahn rick@risg.org http://www.risg.org "Roman Bystrianyk" news:1103302660.105182.66630@z14g2000cwz.googlegroups.com... > http://www.healthsentinel.com/news.php?event=news_print_list_item&id=476 > > "Celebrex Trial Halted After Heart Attacks", Reuters UK, December 17, > 2004, > Link: > http://www.reuters.co.uk/newsArticle.jhtml;jsessionid=RFCKBYLM1PYWECRBAEZSFFA?type=healthNews&storyID=7126735 > > A government-sponsored trial of Pfizer Inc.'s blockbuster arthritis > drug Celebrex was halted after patients taking the medicine had more > than twice as many heart attacks as patients taking a placebo, the > company said on Friday. > > Shares of Pfizer, a component of the Dow Jones industrial average, fell > 17 percent in early trading following news of the long-term trial, > sponsored by the National Cancer Institute. > > The heart-attack findings for Celebrex come only 10 weeks following > Merck & Co.'s recall of its similar arthritis drug, Vioxx, after a > study found the drug doubled the incidence of heart attack and stroke > among patients taking it to prevent colon polyps that cause cancer. > Both drugs are from a class known as COX-2 inhibitors. > > "This does not bode well for COX-2 inhibitors in general," said Ira > Loss, an analyst at Washington Analysis. "The sense had been that > Celebrex is somehow different from the others." > > A Pfizer spokesman declined to say if the company was considering > pulling Celebrex off the market. > > Pfizer said the trial involved patients taking 400-milligram and > 800-milligram daily doses of Celebrex to prevent adenomas, tumors that > grow from glandular tissue. The anti-inflammatory drug was being tested > on the theory that inflammation is a cause of cancer. > > Officials of the U.S. Food and Drug Administration were not immediately > available for comment. > > Vioxx and Celebrex both work by selectively blocking a protein called > COX-2 that has been linked to inflammation. They were both launched in > 1999 and quickly became top-selling drugs, helped by massive television > and print advertising. > > Pfizer also said on Friday that Celebrex was not shown to increase > heart risk in a second long-term trial designed to see if the drug > could prevent colon polyps. > > The New York-based drugmaker said National Cancer Institute officials > decided to halt the other Celebrex trial, to test its ability to > prevent adenomas, after confirming "an approximately 2.5-fold increase > in their risk of experiencing a major fatal or non-fatal cardiovascular > event compared to those taking placebo." > > "They (the NCI) will continue to follow patients in the study," said > Pfizer spokesman Paul Fitzhenry, although patients will no longer be > given Celebrex. > > "We alerted the Food and Drug Administration last night about the > findings," said Fitzhenry. He said he could not elaborate on those > discussions. > > Asked if Pfizer was considering pulling Celebrex off the market in view > of the findings, Fitzhenry said, "We cannot comment beyond our earlier > statement," which did not discuss the possibility of withdrawing the > drug. > Related Discussion: Diabetes and Cholesterol drugs (3 posts) Herbaalex - Most Powerful Herbal Sex Tonic In The World (2 posts) Arthritis healed (1 posts) I feel better all around after takeing my vitamin (3 posts) Top Discussions From Our Archives The rising costs of healthcare Other Discussion Categories Diabetes Symptoms Health Care Policy
|
| ||||||||
 |  |
